![Peter J. Langecker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter J. Langecker
Plus aucun poste en cours
Historique de carrière de Peter J. Langecker
Anciens postes connus de Peter J. Langecker
Sociétés | Poste | Début | Fin |
---|---|---|---|
ONCOTELIC THERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/03/2011 | 15/05/2014 |
Directeur Général | 01/06/2009 | 15/05/2014 | |
Président | 29/12/2011 | 02/01/2014 | |
Independent Dir/Board Member | 01/06/2009 | 30/05/2012 | |
Corporate Officer/Principal | 19/06/2009 | 11/10/2009 | |
President | 11/10/2009 | 15/05/2014 | |
DURECT CORPORATION | Directeur Technique/Scientifique/R&D | 01/05/2006 | 16/06/2009 |
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Directeur Technique/Scientifique/R&D | 01/10/1999 | 01/04/2006 |
Xcyte Therapies, Inc. | Directeur/Membre du Conseil | 01/01/1999 | 30/03/2006 |
Sugen, Inc.
![]() Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Directeur Technique/Scientifique/R&D | 01/01/1997 | 01/01/1999 |
Coulter Pharmaceuticals, Inc.
![]() Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Directeur Technique/Scientifique/R&D | 01/01/1995 | 01/01/1997 |
Schering-Plough Corp.
![]() Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Directeur Technique/Scientifique/R&D | 01/01/1995 | 01/01/1995 |
CYCLACEL PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - | - |
Formation de Peter J. Langecker
Ludwig-Maximilians-Universität München | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Allemagne | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 3 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 9 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
DURECT CORPORATION | Health Technology |
ONCOTELIC THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Xcyte Therapies, Inc. | Health Technology |
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Sugen, Inc.
![]() Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Coulter Pharmaceuticals, Inc.
![]() Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Schering-Plough Corp.
![]() Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
- Bourse
- Insiders
- Peter J. Langecker
- Expérience